Key facts
- This page summarizes Mark Bachleda's Form 3 filing for Lyell Immunopharma, Inc. (LYEL).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jun 2025, 17:42.
Mark Bachleda - 09 Jun 2025 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)
- Reporting relationship
- Director
- Issuer ticker
- LYEL
- Reported as of
- 09 Jun 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 11 Jun 2025, 17:42:27 UTC
- Prior SEC filing
- 20 Mar 2023
- Next SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles Newton, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Bachleda filed Form 3 for Lyell Immunopharma, Inc. (LYEL) on 11 Jun 2025.
Change
- Previous filing in this sequence was filed on 20 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001887762
Primary reporting owner
Bachleda Mark
- Relationship
- Director
- Address
- C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO
- Signature
- /s/ Charles Newton, as Attorney-in-Fact
- Signature date
- 11 Jun 2025
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.